 Shares of Becton Dickinson Co. gained 3.6 in premarket trading on Monday after the diagnostics company announced the launch of a point-of-care COVID-19 antigen test that can detect the coronavirus in 15 minutes. Its the third BD COVID-19 diagnostic test to receive emergency use authorization from the Food and Drug Administration during the pandemic. This will be a game-changer for frontline health care workers and their patients to be able to access a quick diagnostic test for COVID-19, offering results in real-time at convenient locations like retail pharmacies, urgent care centers and doctors offices, Dave Hickey, president of BDs integrated diagnostic solutions business, said in a news release. BDs stock is down 9.9 year-to-date, while the SP; 500 has declined 3.1. 